Ovarian Cancer

Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant.
In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death.
Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status.
Researchers evaluated the connections between safety and efficacy and rucaparib pharmacokinetic exposure in patients with recurrent ovarian cancer.
In the phase 2 OVARIO study, median progression-free survival (PFS) has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities.
Robotic interval debulking surgery is efficient and safe when treating patients with advanced ovarian cancer who are receiving neoadjuvant chemotherapy.
Are patient-reported outcomes (PROs) similar in the placebo and the niraparib groups, suggesting that over the course of treatment niraparib does not adversely affect patients’ quality of life? Results of the PRIMA/ENGOT-OV26/GOG-3012 trial begin to elucidate the answer to this question.
Combination treatment is even more effective in women with ovarian cancer with BRCA mutations or homologous recombination deficiency (HRD)-positive tumors.
The RESPONSE study will help characterize patient characteristics and regional specific therapeutic management strategies adopted in 7 countries to better understand poly (ADP-ribose) polymerase (PARP) inhibitor use and its impact on outcomes.
An analysis of phase 3 data from ARIEL3 was reviewed, providing insight into treatment-emergent adverse events (AEs) in patients receiving maintenance therapy with rucaparib for ovarian cancer.
Page 1 of 10
Results 1 - 10 of 92